These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27830584)

  • 1. Inhaled corticosteroids with combination inhaled long-acting beta
    Tan DJ; White CJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
    Kew KM; Dahri K
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
    Kew KM; Evans DJ; Allison DE; Boyter AC
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.
    Fukuda N; Horita N; Kaneko A; Goto A; Kaneko T; Ota E; Kew KM
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD012066. PubMed ID: 37276335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
    Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM; Thomas EC
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Karner C; Cates CJ; Evans DJ
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD007033. PubMed ID: 22161409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
    Lee HW; Kim HJ; Jang EJ; Lee CH
    Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overuse of long-acting β
    Brunton SA; Hogarth DK
    Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.